What is CAI's current stock price?

CAI (Caris Life Sciences, Inc.) is currently trading at $15.55 with a market cap of $4.40B.

What sector is Caris Life Sciences, Inc. in?

Caris Life Sciences, Inc. (CAI) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CAI a good stock to buy?

Analysts have a Buy consensus on CAI with a price target of $28.60. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CAI Caris Life Sciences, Inc.

Healthcare

$15.55-2.45%ClosedMarket Cap: $4.40B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

7.40

P/S

4.84

EV/EBITDA

34.21

DCF Value

$-13.02

FCF Yield

2.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

68.7%

Operating Margin

15.9%

Net Margin

3.7%

ROE

6.5%

ROA

2.9%

ROIC

14.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$216.2M	$-510.0K	$—
Q4 null	$292.9M	$82.0M	$—
FY null	$812.0M	$-538.0M	$—
Q3 null	$216.8M	$24.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$28.60

Target (Median)

$30.00

Target Range

$21.00 - $38.00

1 Strong Buy10 Buy2 Hold0 Sell0 Strong Sell

JP MorganOverweight

2026-05-08

CitigroupBuy

2026-05-08

BTIGBuy

2026-05-08

Evercore ISI GroupOutperform

2026-04-06

Canaccord GenuityHold

2026-03-13

Trading Activity

Insider Trades

View All

Spetzler David Baxleyofficer: President

SellMon May 18

Power Luke Thomasofficer: See Remarks

SellMon May 18

HALBERT DAVID Ddirector, 10 percent owner, officer: See Remarks

SellMon May 18

Denton John Russelofficer: See Remarks

SellMon May 18

Brille Brian Jdirector, officer: See Remarks

SellMon May 18

Latest News

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026PRNewsWire · Wed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.09

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

Peers

RNA